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 Dear Editor,  
We read with great interest the article published in this journal that addressed the 
complex interactions of antimicrobial stewardship, bacterial drug resistance, sepsis and the 
resultant lay press coverage of these topics in the United Kingdom (UK) currently.1 Oral 
fluoroquinolones have been extensively used to treat a wide range of bacterial infections for 
many years, some of which have been complicated by sepsis, and have been predominately 
used in the primary care setting.  Concerns for overuse of these drugs with resultant 
worsening bacterial resistance, more adverse drug reactions (ADR), and the increased risk 
of Clostridium difficile infection have been a focus  of educational interventions for 
clinicians, the public, and policymakers.1,2 
Earlier trend studies3-7 involving segments of the population in the UK have been 
reported and provide a profile of fluoroquinolone use, but have inconsistent results with no 
detailed information on types of fluoroquinolone-related ADR.  Therefore, the aim of the 
current investigation was to better define contemporary trends in fluoroquinolone use and 
provide a characterization of reported ADR in a large, population-based investigation from 
England.    
Data for all oral antibiotics prescribed in the community setting (outside hospitals) 
in England between 2010 and 2017 were extracted from the Prescription Cost Analysis data 
held by NHS Digital (https://digital.nhs.uk/data-and-
information/publications/statistical/prescription-cost-analysis).  Clinicians who issued the 
prescriptions included physicians, nurse practitioners, and other health care providers, 
including dentists.  For this investigation, a focus on fluoroquinolones was conducted with 
data for each oral fluoroquinolone included.   
National Yellow Card Interactive Drug Analysis Profile data from the Medicines and 
Healthcare Products Regulatory Agency (MHRA) (http://yellowcard.mhra.gov.uk/iDAP/) 
were interrogated and data extracted for all reported ADR to fluoroquinolones that were 
administered orally, or where the route of administration was not stated (reactions to drugs 
administered parenterally, topically or by other routes were excluded), between 2010 and 
2017, to define the rate of ADR with the ADR rate/million prescriptions calculated.  In 
addition, an investigation of the different organ systems involved in an ADR was done for 
comparative purposes among the different oral fluoroquinolones that had been prescribed 
during the study period. 
 
Overall, there were over six million prescriptions for oral fluoroquinolones issued in 
the community setting for the eight years of the study period and ciprofloxacin accounted 
for 91.6% of prescriptions.  Remarkably, there was a 29.8% decline (880,970 for 2010 to 
618,229 for 2017) in ciprofloxacin prescriptions over this period with a decline noted in 
each of the study years (Figure 1).  Prescriptions issued for the other oral fluoroquinolones 
also declined over the study period, except for levofloxacin and ofloxacin where 
prescriptions increased the last two years of the study. 
 For every million prescriptions issued over the study period, 250 resulted in an ADR 
of which 39, 205, and 6 were designated as non-serious, serious, or fatal, respectively.  For 
ciprofloxacin, musculoskeletal reactions were the most frequently reported serious 
reactions (n=889) (Table 1), with tendon disorders being the most common of these 
(n=248).  Nervous system disorders were the next most frequently reported serious 
reactions (n=602) of which paresthesia/dysesthesia/peripheral neuropathy was most 
common (n=196) followed by headaches (n=55) and seizures (n=43).  Of the 25 fatal 
ciprofloxacin-related reactions reported,  ?ǲǳǡ ?ǡ 
of which 3 were attributed to C. difficile infection, and 4 as psychiatric disorders resulting in 
suicide. 
 Previous surveys from England have yielded varied results and are likely due, in 
part, to the variability in healthcare settings of patient cohorts included in databases 
previously used for investigation. 3-7  For example, in one large investigation of 98% 
(n=158) of acute hospitals in the National Health Service that included data from IMS 
Health, a data warehouse, between 2009 and 2013, fluoroquinolone use increased 1.6%.3   
Notably, there were large variations in data comparisons between individual hospitals and 
use included all routes of fluoroquinolone administration.  In contrast, data retrieved from 
the UK THIN database for 2000-2015, which included six percent of the ǯ

Practice patient population, demonstrated a reduction in fluoroquinolone use in recent 
years.7  By inclusion of all community-prescribed oral fluoroquinolone use in England in the 
current work, the trend analysis is likely to be more accurate than that of prior reports.    
In response to largely post-approval ADR,2 serial warnings have been released to 
inform clinicians and patients of potential risks of fluoroquinolone use, which could have 
impacted fluoroquinolone use in the current investigation, along with educational and 
institutional interventions.  Although uncommon, some of these ADR can be chronic and 
result in disabling effects on patients who suffer a diminished quality of life.   
Fluoroquinolone use has been associated with an increased risk of development of 
C. difficile infection, which can be recurrent and severe complications can occur, including 
sepsis and death, the latter of which was seen in the current investigation.  This has been 
the subject of national campaigns in the UK to reduce the use of fluoroquinolones and have 
likely impacted the trend data of fluoroquinolone use described in our study.4,8,9   
The development of fluoroquinolone resistance among aerobic gram-negative bacilli 
has reduced use of this drug class and could have contributed to the trend data displayed in Ǥǡǲǳ
bacteria seen in clinical practice, improvement in in vitro susceptibility of some organisms 
has been described.10 
A major limitation of this work is that information is lacking so that we are unable to 
identify causal factors responsible for the declining use of oral fluoroquinolones in the 
community-based practice in England.  As cited previously, use of the Yellow Card system to 
identify ADR is dependent on passive reporting and is biased by the likelihood that non-
severe reactions are less often reported, as evidenced by the data presented in the current 
survey.   
Based on findings presented herein, there has been a marked reduction in oral 
fluoroquinolone use in the ambulatory care setting in England.  Ciprofloxacin has accounted 
for the bulk of this use; reports of serious ADR coupled with antimicrobial stewardship 
programs that have advocated for diminished use of oral fluoroquinolones have likely been 
responsible for the decline, although cause-and-effect was not evaluated.       
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Table 1 Different types of serious and fatal adverse reactions reported for oral fluoroquinolones between 2010-2017  
 Ciprofloxacin Other Fluoroquinolones All Fluoroquinolones No of Events/million 
Fluoroquinolone Rx 
Type of Adverse Reaction Serious ADR Fatal ADR Serious ADR Fatal ADR Serious ADR Fatal ADR Serious ADR Fatal 
ADR 
Blood and lymphatic system disorders 42 1 8 0 50 1 7.8 0.2 
Cardiac disorders 85 2 25 1 110 3 17.2 0.5 
Congenital, familial & genetic disorders 4 0 0 0 4 0 0.6 0.0 
Ear and labyrinth disorders 83 0 22 0 105 0 16.4 0.0 
Endocrine disorders 1 0 3 0 4 0 0.6 0.0 
Eye disorders 122 0 29 0 151 0 23.6 0.0 
Gastrointestinal disorders 347 1 96 0 443 1 69.1 0.2 
General disorders & administration site 
conditions 
570 7 140 2 710 9 110.7 1.4 
Hepatobiliary disorders 36 2 9 0 45 2 7.0 0.3 
Immune system disorders 43 0 11 1 54 1 8.4 0.2 
Infections and infestations 148 6 42 4 190 10 29.6 1.6 
Injury, poisoning & procedural complications 177 0 68 0 245 0 38.2 0.0 
Investigations 153 0 46 0 199 0 31.0 0.0 
Metabolism & nutrition disorders 63 0 16 0 79 0 12.3 0.0 
Musculoskeletal & connective tissue 
disorders 
889 0 263 0 1152 0 179.7 0.0 
Neoplasms benign, malignant & unspecified 
(incl cysts and polyps) 
2 0 0 0 2 0 0.3 0.0 
Nervous system disorders 602 0 180 3 782 3 122.0 0.5 
Pregnancy, puerperium & perinatal 
conditions 
0 0 0 0 0 0 0.0 0.0 
Product issues 3 0 0 0 3 0 0.5 0.0 
Psychiatric disorders 409 4 149 2 558 6 87.0 0.9 
Renal and urinary disorders 81 0 13 1 94 1 14.7 0.2 
Reproductive system & breast disorders 26 0 1 0 27 0 4.2 0.0 
Respiratory, thoracic & mediastinal 
disorders 
98 0 40 1 138 1 21.5 0.2 
Skin and subcutaneous tissue disorders 353 2 68 0 421 2 65.7 0.3 
Social circumstances 10 0 3 0 13 0 2.0 0.0 
Surgical & medical procedures 4 0 0 0 4 0 0.6 0.0 
Vascular disorders 48 0 10 0 58 0 9.0 0.0 
All Reactions 4399 25 1242 15 5641 40 879.9 6.2 
Notes: These data represent the number of different types of adverse event recorded between 2010-2017 for each fluoroquinolone 
type. Each individual/prescription may be associated with more than one type of adverse event. ADR = Adverse Drug Reaction, Rx = 
Prescriptions. 
 
 
 
 
 
Figure 1.  Number of community oral fluoroquinolone prescriptions in England, 2010-2017 (both 
color and B&W versions). 
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